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Mitochondrial oxidative damage contributes to a wide range of pathologies. One therapeutic strategy to
treat these disorders is targeting antioxidants to mitochondria by conjugation to the lipophilic triphe-
nylphosphonium (TPP) cation. To date only hydrophobic antioxidants have been targeted to mitochon-
dria; however, extending this approach to hydrophilic antioxidants offers new therapeutic and research
opportunities. Here we report the development and characterization of MitoC, a mitochondria-targeted
version of the hydrophilic antioxidant ascorbate. We show that MitoC can be taken up by mitochondria,
despite the polarity and acidity of ascorbate, by using a sufﬁciently hydrophobic link to the TPP moiety.
MitoC reacts with a range of reactive species, and within mitochondria is rapidly recycled back to the
active ascorbate moiety by the glutathione and thioredoxin systems. Because of this accumulation and
recycling MitoC is an effective antioxidant against mitochondrial lipid peroxidation and also decreases
aconitase inactivation by superoxide. These ﬁndings show that the incorporation of TPP function can be
used to target polar and acidic compounds to mitochondria, opening up the delivery of a wide range of
bioactive compounds. Furthermore, MitoC has therapeutic potential as a new mitochondria-targeted
antioxidant, and is a useful tool to explore the role(s) of ascorbate within mitochondria.
& 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Mitochondria are continually exposed to a ﬂux of superoxide
from the respiratory chain and derived reactive oxygen species
(ROS), such as hydrogen peroxide, that lead to oxidative damage
[1]. The levels of ROS formation and oxidative damage are de-
creased or repaired by a battery of mitochondrial antioxidant de-
fenses [2]. However, under many pathological conditions the ca-
pacity of the antioxidant defense and oxidative damage repair
system is exceeded, leading to the mitochondrial oxidative da-
mage that underlies pathology. Consequently, strategies to de-
crease this oxidative damage have considerable therapeuticInc. This is an open access article u
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urphy).potential and the selective targeting of antioxidants to mitochon-
dria by covalent conjugation to the lipophilic triphenylpho-
sphonium (TPP) cation is one widely used approach [3].
TPP is a membrane-permeant lipophilic cation that is rapidly
accumulated several hundred-fold within mitochondria in vivo
driven by the large mitochondrial membrane potential (negative
inside). The most widely used mitochondria-targeted antioxidant
is MitoQ [4], a ubiquinol derivative that prevents mitochondrial
oxidative damage in a wide range of animal models [5] and has
also been assessed in two phase II trials in humans [6,7]. This
approach has been extended to target a wide range of other an-
tioxidants, pharmacophores and probe molecules to mitochondria
in vivo[3,8]. To date however, the compounds that have been so
targeted have been hydrophobic, uncharged and hence largely act
at the matrix-facing surface of the mitochondrial inner membrane.
There is an unmet need to develop mitochondria-targeted anti-
oxidants that act in the matrix. In addition, an aqueous antioxidant
may also act as a redox shuttle connecting antioxidants in the
mitochondrial matrix, such as glutathione, with those within the
membrane, such as Vitamin E.
A compelling candidate for a matrix antioxidant and redoxnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Fig. 1. The redox reactions of ascorbate and the uptake of MitoC by mitochondria.
(A) Antioxidant reactions and recycling of ascorbate. Ascorbate reacts with reactive
species (RS) or with the α-tocopheroxyl radical (α-TO) at the surface of the mi-
tochondrial inner membrane by one electron donation to form the ascorbyl radical.
The ascorbyl radical then dismutates back to ascorbate and dehydroascorbate
(DHA), which can then either hydrolyze irreversibly or be recycled back to ascor-
bate by the GSH/Grx2 and Trx systems. (B) Uptake of MitoC by mitochondria. Mi-
toC, an ascorbate linked to the lipophilic TPP cation by an alkyl chain, is accumu-
lated several hundred fold within the mitochondrial matrix driven by the mem-
brane potential (Δψ) and there acts as an antioxidant.
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gatively charged at physiological pH (pKa 4.2 [9]). Ascorbate
functions as an antioxidant in the aqueous phase through one
electron donation to quench radicals, and also has an important
role as a biological reductant [10]. The ascorbyl radical thus gen-
erated dismutates to ascorbate and dehydroascorbate (DHA),
which is unstable and hydrolyses spontaneously if it is not rapidly
reduced back to ascorbate by reductants such as glutathione [11–
13] (Fig. 1A). Ascorbate also interacts with biological membranes
to recycle the lipid-soluble antioxidant Vitamin E from the
αtocopheroxyl radical back to the active antioxidant [13,14]
(Fig. 1A). Thereby ascorbate links matrix reductants to antioxidant
processes within the inner membrane [11]. There is a pool of as-
corbate within mammalian mitochondria [15] that arises from
either sodium-coupled ascorbate accumulation [16], or by uptake
of DHA via the mitochondrial GLUT-10 transporter followed by
reduction to ascorbate within the matrix [17]. However, the po-
tential role(s) of ascorbate in the mitochondrial matrix have not
been explored in depth and the physiological importance of as-
corbate as an antioxidant and/or as a one electron reductant
within mitochondria is unclear.
Thus there is a strong justiﬁcation for developing a mitochondria-targeted ascorbate to see if this decreases mitochondrial oxidative
damage and to explore the function of ascorbate within the matrix
(Fig. 1B). However, it is unclear if a hydrophilic and polar carbohy-
drate such as ascorbate can be transported through a biological
membrane by conjugation to TPP. Furthermore, as ascorbic acid has a
pKa of 4.2 [9], under physiological conditions a TPP-conjugated as-
corbate would be a zwitterion, whose neutrality may prevent uptake
into mitochondria driven by the membrane potential [18,19].
Therefore, in addition to its potential utility, the development of a
mitochondria-targeted ascorbate presents interesting challenges,
which, if overcome, would expand the groups that can be targeted to
mitochondria. Therefore here we synthesized TPP-conjugated ascor-
bate variants (MitoC) differing in lipophilicity to determine whether
ascorbate can be targeted to mitochondria. We show that the 11-
carbon version of MitoC is accumulated by energized mitochondria
and is continually recycled to its active antioxidant form by the mi-
tochondrial glutathione and thioredoxin systems, making MitoC a far
more effective mitochondrial antioxidant than ascorbate itself.1. Materials and methods
1.1. Synthetic chemistry
All reagents were from Sigma-Aldrich, unless otherwise stated.
1H, 13C and 31P NMR spectra were acquired on Varian AR 500 or
MR 400 spectrometers. Chemical shifts are given in ppm on the δ
scale referenced to the solvent peaks. High-resolution mass spec-
tra were recorded on a Bruker microTOF electrospray mass spec-
trometer. HPLC analysis was carried out using a Shimadzu pro-
minence system on a C18 column (Phenomenex Prodigy ODS
(3) 5 μm 100 Å, 2503 mm) gradient elution 10% acetonitrile
(ACN)/0.05% triﬂuoroacetic acid (TFA) to 100% ACN/0.05% TFA over
12.5 min at 0.5 ml min1 with detection at 210 and 254 nm.
Attachment of a TPP function at C-6 was achieved using a
connecting sulfur atom. This was based on literature precedence
and our previous experience with TPP thiols. Reaction of 6-bromo-
6-deoxy-L-ascorbic acid with TPP propylthiol [20] using a mod-
iﬁcation of the published procedure [21], but avoiding the use of
sodium hydroxide, worked effectively (Fig. 2A). TPP thiols for the
longer chain variants were produced from the corresponding
bromoalkene [22] (Fig. 2B). However, as initial attempts to isolate
long chain TPP thiol compounds from the hydrolysis reaction gave
signiﬁcant disulﬁde formation, we used an initial basic pH to hy-
drolyze the TPP thioacetate and then rapidly decreased the pH.
The bromoalkene precursors [23,24] for the C17 and C21 com-
pounds were prepared by haloalkylation of the Grignard reagent
prepared from 11-bromoundecene [25]. Details of the synthetic
chemistry are given in the Supplemental Materials.
1.2. Characterisation of MitoC
Stock solutions of TPP compounds were made up in absolute
ethanol, ﬂushed with argon and stored at –20 °C. L-ascorbic acid was
used in all experiments for comparison with MitoC. Most reactions
were carried out in KCl buffer (120 mM KCl, 1 mM EGTA, 10 mM
HEPES, pH 7.2). Reversed phase HPLC (RP-HPLC) measurements were
obtained using a C18 column (Jupiter 300 A, Phenomenex
s
) with a
Widepore C18 Guard Column (Phenonmenx
s
), a 2 ml sample loop
and a Gilson 321 pump. For this, MitoC (10 nmol) and the internal
standard TPMP (10 nmol) were added to 750 mL KCl buffer and in-
cubated at 37 °C. Samples were diluted with 250 mL buffer B (0.1%
TFA in HPLC-grade ACN), ﬁltered through a Milipore
s
Millex
s
syr-
inge-driven ﬁlter unit (0.22 mm) and separated by RP-HPLC. A gra-
dient of buffer A and B was run at 1 ml/min (%B): 0–5 min, 5–15%;
5–31 min, 15–100%; 31–35 min, 100–5%. Peaks were detected at
AC
B
Fig. 2. Synthesis and structures of MitoC variants. (A) Synthesis of MitoC3. The synthesis of MitoC3 shows the reaction between bromoascorbic acid and TPP-propylthiol
(B) Synthesis of the TPP-alkylthiols of different lengths. By altering the lengths of the alkyl chain [TPP(CH2)nSH] a series of MitoC compounds of different hydrophobicities
can be generated. (C) Structures of the compounds investigated. The simplest TPP cation (TPMP), ascorbic acid and the MitoC variants: MitoC3, MitoC11, MitoC17 and MitoC21.
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Fig. 3. Mitochondrial accumulation of MitoC variants. (A) Relative hydrophobicity of MitoC variants. RP-HPLC of a mixture of 10 nmol each of the MitoCn variants (n¼3, 11, 17
and 21). (B) Uptake of TPMP into mitochondria. TPMP (2.5 μM) was incubated with mitochondria (0.5 mg protein/ml) in KCl buffer supplemented with rotenone (4 mg/ml)
and were energised with succinate (10 mM)7FCCP (1 mM) and uptake assessed by RP-HPLC. (C) Lack of uptake of MitoC3 by mitochondria. MitoC3 (2.5 μM) was incubated
with mitochondria as in (B) and the amounts in the mitochondrial pellet and supernatant (SN) were determined after 5 min by RP-HPLC. (D) The accumulation ratios (ACRs)
of MitoC3 and TPMP. The ACRs of MitoC3 (2.5 μM) and TPMP (2.5 μM) were measured as described in (B)7FCCP. Data are means7SEM of three independent incubations.
(E) Mitochondrial uptake of MitoC11. Mitochondria were incubated with MitoC11 (2.5 μM) and TPMP (2.5 μM)7FCCP as in (B) and the amounts of the compounds in the
pellet determined by RP-HPLC. (F) The ACR for MitoC11 was determined as in (D). Data are means7SEM of three independent incubations. (G) Uptake of MitoC11 by
mitochondria measured using an ion-selective electrode. An electrode sensitive to the TPP moiety of MitoC was inserted into KCl buffer supplemented with 4 mg/ml rotenone.
After calibration with 51 mM MitoC (arrowheads), mitochondria (RLM) (0.5 mg protein/ml) were added, followed by 10 mM succinate (SUC) and 1 mM FCCP. This trace is
representative of three independent experiments. Statistical signiﬁcance was determined by a two-tailed Student’s t-test (nnpo0.01, nnnpo0.001).
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MitoC standards were used to determine elution times and peak
areas were calculated using the Chart 5 (ADInstruments
s
) software.
To assess oxidation MitoC (20 nmol) or ascorbic acid (15 nmol) was
incubated at 37 °C in KCl buffer and UV absorption spectra obtained
using a Shimadzu UV-2501 PC spectrophotometer. To measure the
pKa we monitored changes in the UV absorbance at 265 nm for as-
corbic acid (30 μM) or MitoC (15 μM) in KCl buffer at 25 °C at dif-
ferent pH values. The pKa values were calculated by ﬁtting to the
Henderson-Hasselbalch equation,pK pH loga
A A
A A10
N pH
pH I( )= − −− , where AN and AI are absorbances of
the protonated and ionised forms, respectively, and ApH is the
absorbance at the respective pH. pKa values obtained were:
4.2870.09 and 11.0870.43 for MitoC and 4.3670.29 and
11.2770.16 for ascorbic acid.
1.3. Mitochondrial preparation
Liver mitochondria (RLM) were prepared from 6 to 13 week old
female Wistar rats (up to 250 g) by homogenization followed by
BA
C
Fig. 4. MitoC uptake dependence on the mitochondrial pH gradient. (A) Effect of nigericin on the uptake of MitoC and TPMP. The ACRs of MitoC (2.5 μM) and TPMP (2.5 μM)
were measured simultaneously as in Fig. 3D7nigericin (100 nM). (B) Accumulation of MitoC normalized to that of TPMP. Data in (A) and (B) are means7SEM of three
independent incubations. Statistical signiﬁcance was determined by a two-tailed Student’s t-test (npo0.05, nnpo0.01). (C) Schematic of mechanism of uptake of MitoC by
energized mitochondria. A TPP cation conjugated to an ascorbate moiety generates a membrane-impermeant zwitterion and a membrane-permeant singly charged cation
that is accumulated in response to Δψm. The pH gradient will further enhance the accumulation of MitoC.
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HCl, 1 mM EGTA, pH 7.4. Protein concentration was determined by
the biuret assay using bovine serum albumin as a standard. In-
cubations were carried out in KCl buffer at 37 °C, if not otherwise
stated. Mitochondrial uptake of MitoC measured using an ion-se-
lective electrode (ISE) sensitive to the TPP moiety was done as
previously described [26]. Linoleic acid hydroperoxide (LAH) was
made as described [27].
1.4. Mitochondrial uptake of MitoC measured by RP-HPLC
RLM (0.5 mg protein/ml) were incubated in 4 ml KCl buffer
supplemented with rotenone (4 mg/ml) and TPMP (2.5 mM) and the
respective MitoC variant (2.5 mM) in open plastic tubes (Sarsteds)
in a shaking water bath at 37 °C. Respiration was initiated by the
addition of succinate (4 mM). When indicated FCCP (1 mM) was
added 4 min later. Five min later mitochondria were pelleted by
centrifugation (7500 x g for 5 min at 4 °C). Supernatants were
removed and stored at 4 °C in eppendorf tubes until analysis.
Mitochondrial pellets were extracted in 250 mL buffer B followed
by centrifugation (7500 x g for 5 min). The supernatant (250 mL)
was removed and stored at 4 °C in glass vials (Chromacol
s
). All
samples were diluted to 25% ACN with buffer A, and separated by
RP-HPLC as described above. TPMP and MitoC standards were used
to determine peak areas and elution times, using the
Chart 5 software (ADInstruments
s
). Accumulation ratios (ACR)
between the mitochondrial matrix and the extra-mitochondrial
environment were calculated by normalizing the peak areas tomitochondrial volume (0.5 mL/mg protein [28]) and to 4 ml for the
extra-mitochondrial environment.
1.5. Oxidation and reduction of MitoC
Oxidation of MitoC and ascorbic acid was followed by the de-
crease in absorbance at 265 nm at 25 °C in KCl buffer. To generate a
superoxide ﬂux we used xanthine oxidase (XO, Sigma) (0.1 U/ml)
and acetaldehyde (10 mM), in the presence of catalase (5 mg/ml).
Reaction of MitoC and ascorbic acid was followed by coupling their
reductive recycling to an NADPH-linked reductase and measuring
the absorbance at 340 nm. Thioredoxin reductase (TrxR) and
thioredoxin (Trx) were from Escherichia coli (Sigma), ascorbate
oxidase (AO) was from Cucurbita sp. (Sigma) and His-tagged glu-
taredoxin-2 (Grx2) was prepared and puriﬁed as described [29].
1.6. Oxidative damage assays
To measure thiobarbituric acid reactive species (TBARS), mi-
tochondria (2 mg protein/ml) were incubated at 37 °C with shaking
for 5 min in 100 mM KCl, 10 mM Tris-HCl, pH 7.6 supplemented
with 4 μg/ml rotenone with 10 mM succinate or 1 mM FCCP as in-
dicated. Then 0.8 ml aliquots were mixed with 400 ml 0.5% thio-
barbituric acid in 35% HClO4 and 60 ml 2% butylated hydroxytoluene
(BHT) in DMSO, and then heated at 100 °C for 15 min, diluted with
2 ml water and extracted into 2 ml n-butanol. TBARS were de-
termined ﬂuorometrically (λexcitation¼515 nm; λemission¼553 nm)
and expressed as nmol malondialdehyde (MDA) by comparison
A B
DC
FE
Fig. 5. Characterization of MitoC oxidation. (A) UV-scanning spectra of MitoC. Spectra of (15 μM) of MitoC11 in KCl buffer were measured over time. (B, C) Oxidation of
MitoC11 measured by RP-HPLC. MitoC11 (10 μM) was incubated in KCl buffer7DTPA (5 mM) with 10 mM TPMP as an internal standard. At various times samples were
analyzed by RP-HPLC. (C) Shows the levels at t¼0 and t¼24 h and (D) shows the full time course where data are means7SEM of three experiments. (D-F) Reaction of
ascorbate or MitoC with oxidants. MitoC (20 mM) or ascorbate (20 mM) was incubated in KCl medium and the decrease of absorbance at 265 nm measured. Additions were
H2O2 (100 mM), ROO (generated by spontaneous homolysis of 2,2′-azobis(2-amidinopropane) dihydrochloride (10 mM)), superoxide or FeCl3 (30 mM). Generation of su-
peroxide was initiated by 10 mM acetaldehyde in the presence of xanthine oxidase (0.1 U/ml) and catalase (5 mg/ml). The oxidation of ascorbate and MitoC by superoxide was
prevented by including Cu, Zn SOD (100 U/ml).
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MitoPerox ﬂuorescence was measured using a Shimadzu RF-301 PC
ﬂuorimeter ((λexcitation¼495 nm; λemission¼520 nm; slit widths
3 nm; scan speed, fast). For aconitase inactivation, mitochondria
(2 mg protein/ml) were incubated with succinate (10 mM) to in-
duce reverse electron transfer (RET) and inhibited by rotenone
(4 μg/ml) [30], or incubated with paraquat. Aconitase activity was
assayed in a 96-well plate as described previously [31]. Brieﬂy, ali-
quots (10 ml) of snap-frozen mitochondrial incubations were in-
cubated in 190 ml Tris-HCl (50 mM, pH 7.4), MnCl2 (0.6 mM), so-
dium citrate (5 mM, pH 7.0), NADPþ (0.4 mM), Triton X-100 (0.1% v/
v), and isocitrate dehydrogenase (0.8 U ml1) in triplicate at 30 °C,
and NADPH (ε340¼6.22103 M1 cm1) was monitored over
20 min at 340 nm using an ELx808 Ultra Microplate Reader (Bio-Tek
Instruments). Background NADPH formation was determined in the
presence of ﬂuorocitrate (100 μM) and was always less than 10% of
the initial rate.2. Results and Discussion
2.1. Synthesis and hydrophobicity of MitoC3-21
To direct ascorbate selectively to mitochondria we conjugated
it to the lipophilic TPP cation (Fig. 2B). As we were concerned that
the polarity of the ascorbate moiety might disrupt uptake we
made a series of TPP-ascorbate conjugates of varying hydro-
phobicities by increasing the length of the alkyl chain linking to
the TPP cation [32]. Four MitoCn variants with linkers of 3, 11, 17
and 21 methylene groups were synthesized (Figs. 2A and B), and
are shown in Fig. 2C, along with ascorbic acid and the simple TPP
lipophilic cation TPMP. These MitoC variants eluted from a RP-
HPLC C18 column in order of their hydrophobicity (Fig. 3A).
2.2. Dependence of MitoC mitochondrial uptake on hydrophobicity
MitoC11 had pKa values of 4.2870.09 and 11.0870.43, compared
BA
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Fig. 6. Recycling of MitoC by glutathione. (A) RP-HPLC assessment of MitoC oxidation. MitoC (10 nmol) and a TPMP internal standard (10 mM) after 0 or 24 h in KCl buffer
with DTPA (5 mM) and GSH (10 mM). (B) Quantiﬁcation of the effect of GSH on MitoC stability. MitoC content normalised to TPMP after 24 h7GSH as described in (A), or
when GSH was added after 24 h incubation. Data are means7SEM of three experiments. Statistical signiﬁcance was determined by two-tailed Student's t-test (nnnpo0.001).
(C) Regeneration of oxidised MitoC by GSH. Time course of absorbance at 265 nm for MitoC (20 mM) in KCl buffer. Oxidation was initiated by the addition of AO (1 U/ml). After
complete oxidation GSH (10 mM) was added. (D) The experiment in (C) was repeated and analyzed by RP-HPLC. RP-HPLC chromatogram of MitoC (30 mM) after oxidation
with AO as in (C). (E) Recycling of MitoC or ascorbic acid by the GSH/Grx2 system. Recycling was followed at 340 nm by the oxidation of NADPH (0.3 mM) by GR (0.4 U/ml)
with either GSH (10 mM), or GSH (10 mM) and glutaredoxin (Grx2; 1 U/ml). After 3 min of equilibration test compound (20 mM) was added and oxidation initiated by the
addition of AO (1 U/ml). Grx2 in the absence of GSH was indistinguishable from “no additions” and this trace has been omitted. (F) Rate of NADPH oxidation by glutathione
reductase. The initial rate of NADPH oxidation following addition of AO determined in (E) was quantiﬁed. Data are means7SEM of three independent incubations. Statistical
signiﬁcance was determined by two-tailed Student's t-test (npo0.01).
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of ascorbate to a TPP cation did not affect its pKa and under physio-
logical conditions MitoC will be a zwitterion whose neutrality may
preclude uptake by mitochondria in response to the membrane po-
tential [18,19]. However, a weak acid conjugated to a TPP cation was
taken up into mitochondria in response to the membrane potential by
crossing the membrane in a protonated, monocationic form [18,19].
Given that less than 0.1% of MitoC would be in the monoprotonated
form it was unclear if uptake could occur for MitoC. A further potential
limitation to the mitochondrial uptake of MitoC is whether the po-
larity of the ascorbate moiety, even when protonated and neutral,
would prevent uptake through the inner membrane. This difﬁculty
may arise because the ability of a TPP cation to cross a membrane is abalance between lipophilicity and polarity, with hydrophobicity en-
hancing uptake [18,32]. Increasing hydrophobicity of a TPP cation can
enable the threshold for membrane transport to be reached [32],
therefore we assessed whether any of the MitoC variants shown in
Fig. 2C were taken up by mitochondria.
Incubation of the simple TPP cation, TPMP with energized
mitochondria followed by isolation by centrifugation and analysis
by RP-HPLC showed extensive uptake into mitochondria that was
blocked by dissipating the membrane potential with the un-
coupler FCCP (Fig. 3B). In contrast, there was no uptake into mi-
tochondria of MitoC3, which remained in the supernatant (Fig. 3C).
To further quantify uptake we also measured the accumulation
ratio (ACR), that is, the amount of TPMP or MitoC3 in mitochondria
BA
DC
Fig. 7. Recycling of MitoC or ascorbic acid by thioredoxin. (A, B) Recycling by thioredoxin. Ascorbic acid (A) or MitoC (B) was followed by the oxidation of NADPH (0.3 mM) at
340 nm by TrxR (1 U/ml)7Trx (1 U/ml). After 3 min of equilibration test compound (20 mM) was added and oxidation initiated by the addition of AO (1 U/ml). (C) Rate of
NADPH oxidation by TrxR. The initial rate of NADPH oxidation following addition of AO determined in (A) and (B) were quantiﬁed. Data are means7SEM of three in-
dependent incubations. (D) Effect of incubation with mitochondria on MitoC redox stateMitochondria (0.5 mg protein/ml) were incubated in rotenone (4 mg/ml) supple-
mented KCl buffer that contained MitoC (10 mM) in the presence (white bar), or absence (black bar) of succinate (10 mM). The grey bar shows MitoC incubated without
mitochondria. Ratios of A.U.C. of MitoC expressed as percentage loss. After 60 min incubation the amount of MitoC remaining was assessed by RP-HPLC. Data are mean-
s7SEM of independent incubations (n¼3-5). Statistical signiﬁcance was determined by two-tailed Student’s t-test (nnn Po0.001).
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not taken up due to its polarity, we next assessed the more hy-
drophobic MitoC11, simultaneously with TPMP to facilitate com-
parison (Fig. 3E). Both MitoC11 and TPMP were accumulated within
energized mitochondria, and this uptake was prevented by FCCP
(Figs. 3E and F). The difference in uptake between MitoC11 and
MitoC3 was not due to a decrease in the pKa of MitoC3, for example
caused by closer proximity of the cation, as the ﬁrst pKa of MitoC3
(4.15) was very similar to that for MitoC11 (4.28). Therefore MitoC11
is taken up by mitochondria in a membrane potential-dependent
manner while MitoC3 is not, presumably because of its greater
hydrophilicity. MitoC17 and MitoC21 showed extensive adsorption
to de-energized mitochondria (data not shown), due to their hy-
drophobicity, so while they are probably accumulated in response
to the membrane potential, they are too hydrophobic to be easily
worked with. Therefore we focused on MitoC11 and refer to it as
MitoC from now on.
MitoC (pKa 4.28) is most likely taken up by mitochondria as
the protonated, monocationic form, as was the case for a TPP-
conjugated carboxylic acid (pKa 4.9) [19]. In that case, the ac-
cumulation of the weak acid into the basic mitochondrial matrix
synergized with the membrane potential to enhance uptake [19].
To see if the mitochondrial pH gradient increased MitoC uptake we
abolished the pH gradient with the Kþ/Hþ exchanger nigericin. As
nigericin increases the membrane potential to the same extent as
it decreases the pH gradient, we measured the uptake of MitoC
and TPMP simultaneously to control for the change in membrane
potential (Fig. 4A). Nigericin increased the uptake of TPMP, due to
the rise in membrane potential, but had a negligible effect on
MitoC uptake, probably due to the increase in uptake due to the
higher membrane potential being counteracted by the loss of the
pH-dependent accumulation of its weak acid (Fig. 4A). Normal-
izing the uptake of MitoC to that of TPMP corrected for this effect
of membrane potential; nigercin decreased the potential-correcteduptake of MitoC (Fig. 4B), hence the pH gradient enhances the
accumulation of MitoC in the same way as for a TPP-conjugated
carboxylic acid [19]. MitoC is taken up into mitochondria via the
protonated, monocationic form, and its uptake is greater than that
of the cation alone due to the pH gradient (Fig. 4C).
2.3. Oxidation of MitoC
Ascorbate is a reductant and antioxidant through one electron
donation, thereby generating the ascorbyl radical, which in turn
dismutates to dehydroascorbate (DHA) and ascorbate (Fig. 1A). If
DHA is not recycled back to ascorbate it hydrolyzes irreversibly. UV
absorption showed that the ascorbate moiety of MitoC was lost
under biological conditions (Fig. 5A). RP-HPLC also showed ex-
tensive degradation of MitoC with a half-life of 2.3 h (Figs. 5B
and 6C). MitoC loss was slowed by chelating redox-active metals
(Fig. 5C), consistent with its oxidation to MitoDHA followed by
spontaneous hydrolysis.
We next assessed howMitoC reacts with physiological oxidants
by observing its ascorbate moiety at 265 nm (Figs. 5D and E). Both
ascorbate and MitoC are rapidly oxidized by superoxide and alkyl
peroxyl radicals, but not by hydrogen peroxide (Figs. 5D and E).
Ascorbate reduces transition metals maintaining their bioavail-
ability [10], and MitoC also reduced ferric iron (Fig. 5F). Therefore
conjugation to TPP does not impair ascorbate redox chemistry, so
MitoC should be an effective antioxidant and reductant.
2.4. Recycling of MitoC
To be an effective antioxidant in vivo the unstable MitoDHA
formed following one electron reduction by MitoC must converted
back to MitoC before it decomposes. To see whether MitoC could be
recycled we assessed the effect of glutathione (GSH) on MitoC
oxidation over 24 h (Fig. 6A). MitoC was maintained in its active,
A B
DC
E
Fig. 8. Prevention of mitochondrial oxidative damage by MitoC. (A) Effect of MitoC on mitochondrial lipid peroxidation assessed by TBARS. Mitochondria (2.5 mg protein/ml)
were incubated with rotenone (4 mg/ml) with MitoC (5 mM or 0.5 mM) or TPMP (5 mM), in the presence (þ) or absence (-) of 10 mM succinate. After 2 min preincubation H2O2
(100 mM) and FeCl2 (30 mM) were added and 5 min later TBARs were quantiﬁed. Data are means7SEM of three independent incubations. (B) Concentration-dependent effect
of MitoC on mitochondrial lipid peroxidation assessed by TBARs formation. Mitochondria were incubated as in A with MitoC (0.01–5 mM) or ascorbate (5–2500 mM) and
TBARS formation was quantiﬁed. (C) Time course of MitoPerox ﬂuorescence. Mitochondria (0.5 mg protein/ml) were incubated7succinate (10 mM) in the presence of LAH
(25 mM), 1 mMMitoPerox75 mMMitoC,75 mM ascorbic acid. (D) Effect of MitoC on aconitase inactivation by reverse electron transfer (RET). Mitochondria (2 mg protein/ml)
were incubated with succinate (10 mM) for 7 min. Rotenone (4 μg/ml) was added to a control incubation to prevent RET. Test compounds were present at 5 μM. (E) Effect of
MitoC on aconitase inactivation by paraquat (PQ). Mitochondria (2 mg protein/ml)7MitoC (5 μM) were incubated with succinate (10 mM) and PQ for 7 min and then
analyzed for aconitase activity. Data are means7SEM of three independent incubations. Statistical signiﬁcance was determined by a two-tailed Student's t-test (nPo0.05,
nn Po0.001, nnn Po0.0001).
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ever addition of GSH at the end of the incubation did not restore
MitoC (Fig. 6B). To rapidly oxidize MitoC to MitoDHA we used as-
corbate oxidase (AO, L-ascorbate:O2 oxidoreducatse, EC 1.10.3.3)
[12], which converted MitoC to MitoDHA, as measured by UV ab-
sorbance (Fig. 6C) and RP-HPLC (Fig. 6D). GSH added immediately
after MitoC oxidation could restore MitoC (Figs. 6C and D), but not
when added 2 min later (Figs. 6C and D). To further assess MitoC
recycling by GSH, we coupled GSH oxidation to NADPH consump-
tion through glutathione reductase (Figs. 6E and F). Addition of AO
led to GSH oxidation as MitoDHA was recycled back to MitoC
(Figs. 6E and F). The mitochondrial glutaredoxin2 isoform (Grx2),
which can act as a DHA reductase utilizing GSH [2,32–34], en-
hanced the recycling of MitoDHA after AO oxidation (Figs. 6E and F).
These ﬁndings are consistent with GSH and Grx2 recycling Mi-
toDHA back to MitoC before its irreversible hydrolysis (t1/2 5 min).The thioredoxin (Trx) system can also recycle DHA to ascorbate
[35]. To assess whether Trx could also recycle MitoC we incubated
ascorbate or MitoC in the presence of E. coli thioredoxin reductase
(TrxR), coupling MitoDHA recycling to NADPH oxidation (Fig. 7).
When MitoC was oxidized by AO there was no recycling by TrxR,
although the mammalian form of TrxR, which is a selenoenzyme
unlike that from E. coli, is likely to directly reduce MitoDHA [35].
Trx addition increased NADPH oxidation (Fig. 7A-C), suggesting
MitoDHA is recycled back to MitoC by direct reaction with Trx,
which is then recycled by TrxR. Thus within mitochondria Mi-
toDHA will be recycled back to MitoC by the GSH/Grx2 and Trx/
TrxR systems. Supporting this, incubating MitoC with energized
mitochondria prevented its degradation (Fig. 7D).
2.5. Prevention of mitochondrial oxidative damage by MitoC
MitoC is accumulated by mitochondria, can sequester reactive
P.G. Finichiu et al. / Free Radical Biology and Medicine 89 (2015) 668–678 677species and then be recycled. To see if these properties made
MitoC an effective mitochondria-targeted antioxidant, we assessed
whether it could protect against lipid peroxidation (Fig. 8A). To do
this we induced lipid peroxidation in mitochondria and then
measured its extent by quantifying TBA reactive species (TBARS)
(Fig. 8A). While the TBARS assay is relatively insensitive and has a
signiﬁcant number of limitations for assessing endogenous oxi-
dative stress, it was appropriate to assess the effect of MitoC on
preventing lipid peroxidation in vitro induced by exogenous oxi-
dants. This assay showed extensive lipid peroxidation that was
blocked by low MitoC concentrations, (0.5 mM), while the TPMP
cation alone was not protective (Fig. 8A). Mitochondrial en-
ergization with succinate enhanced protection, due to accumula-
tion and recycling of MitoC (Fig. 8A). A dose-response curve
showed that MitoC was protective against lipid peroxidation at
several-hundred fold lower concentrations than ascorbate
(Fig. 8B).
To further analyze the effect of MitoC on lipid peroxidation we
used a mitochondria–targeted lipid-peroxidation probe, MitoPer-
Ox [36] and initiated peroxidation with linoleic acid hydroper-
oxide (LAH), which increased MitoPerOx ﬂuorescence (Fig. 8C).
The increase in ﬂuorescence was largely prevented by MitoC, but
not by the same concentration of ascorbate (Fig. 8C). MitoC was
only transiently protective against lipid peroxidation in de-en-
ergized mitochondria (Fig. 8C), presumably due to its lack of
concentration and recycling within the matrix. As MitoC does not
react with peroxides the protection is most likely due to its re-
duction of the oxygen and carbon centred radicals generated
during lipid peroxidation. This reaction may be facilitated by Mi-
toC adsorbing to the matrix-facing surface of the inner membrane,
as occurs for MitoQ [31]. MitoC may also recycle the α-tocopher-
oxyl radical by shuttling electrons from the GSH and Trx systems,
thereby facilitating the role of Vitamin E as a membrane-based
antioxidant [13,14].
To see if MitoC was also protective against oxidative damage in
the matrix we investigated the superoxide-dependent inactivation
of mitochondrial aconitase. Superoxide that evades MnSOD can
inactivate aconitase rapidly (k 107 M1s1). As ascorbate reacts
relatively rapidly with superoxide (k 3105 M1s1[10]) the
accumulation of MitoC within the matrix may protect aconitase by
sequestering superoxide. To assess this we induced superoxide
production by reverse electron transport (RET) from complex I,
which lowered aconitase activity (Fig. 8D). MitoC decreased this
damage, while ascorbate and the mitochondria-targeted anti-
oxidants MitoQ and MitoTEMPOL did not (Fig. 8D). The redox cy-
cler paraquat produces superoxide within mitochondria [37] and
also led to aconitase inactivation that was decreased by MitoC
(Fig. 8E). While aconitase protection by MitoC is likely to be largely
due to superoxide sequestration, MitoC may also reduce ferric iron
to the ferrous form (Fig. 6F), and thereby help reactivate aconitase
by facilitating iron reinsertion, as happens for cytosolic aconitase
[38,39]. In summary, these ﬁndings show that MitoC is an effective
mitochondria-targeted antioxidant due to its accumulation and
recycling within mitochondria.3. Conclusion
The targeting of antioxidants and bioactive molecules to mi-
tochondria by conjugation to the lipophilic TPP cation is effective
both as a therapeutic strategy and as a tool in the investigation of
mitochondrial function. To date, these molecules have comprised a
hydrophobic moiety conjugated to a TPP cation that drives their
selective uptake into mitochondria. However, it was unknown if
ionisable and polar bioactive compounds could be targeted to
mitochondria. Here we have shown that TPP can be used to targetascorbate to mitochondria. That MitoC is accumulated, despite
being present largely as a zwitterion, indicates that it is taken up
as the protonated monocation, and uptake was enhanced by the
pH gradient [19]. The uptake of MitoC by mitochondria required a
long hydrophobic chain to counteract the polarity of the carbo-
hydrate ascorbate. Therefore the TPP delivery system can be ex-
panded to deliver polar and ionisable groups to mitochondria.
MitoC is a potent mitochondria-targeted antioxidant, several
hundred-fold more potent in preventing mitochondrial oxidative
damage than unmodiﬁed ascorbate. This was because it is accu-
mulated several hundred-fold by mitochondria. The polarity of
MitoC may enable it to act as an antioxidant in the aqueous matrix
as well as an electron shuttle to the membrane. These unique
aspects of its antioxidant action make MitoC a useful complement
to more hydrophobic compounds such as MitoQ. MitoC expands
the therapeutic and investigational uses of mitochondria-targeted
antioxidants and will be a useful tool to explore the role of as-
corbate within mitochondria.Acknowledgements
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